2008 Giro d'Italia, Stage 1 to Stage 11

Oculis to Present a Late-Breaking Abstract at the American Academy of Ophthalmology 2023 Annual Meeting on the Positive Stage 1 Results from Phase 3 DIAMOND Trial for Diabetic Macular Edema

Retrieved on: 
Wednesday, November 1, 2023
Cerebral edema, CME, Intravitreal injection, Diabetic retinopathy, DME, AAO, Dexamethasone, Diabetes, Inflammation, OCS, American Academy, 2008 Giro d'Italia, Stage 1 to Stage 11, American Academy of Ophthalmology, Annual general meeting, Paratriathlon, Pain, Patient, Trial of the century, Retina, Pharmaceutical industry

A 12-week Phase 2/3 Double-masked, Randomized, Multicenter Study of OCS-01 Eye Drops in Diabetic Macular Edema (DME)

Key Points: 
  • A 12-week Phase 2/3 Double-masked, Randomized, Multicenter Study of OCS-01 Eye Drops in Diabetic Macular Edema (DME)
    OCS-01 is Oculis’ lead product candidate and the first investigational eye drop for both front and back of the eye indications, with positive results in Stage 1 of the Phase 3 DIAMOND trial for DME announced in May 2023, and positive Phase 3 OPTIMIZE trial results for inflammation and pain following cataract surgery announced in August 2023.
  • Furthermore, the investigator-initiated LEOPARD study evaluating OCS-01 for the treatment of cystoid macular edema (CME) enrolled its first patient in August 2023.
  • Leveraging Oculis’ proprietary OPTIREACH® technology, OCS-01 is a novel, high concentration (15 mg/ml), topical formulation of dexamethasone.
  • If approved, OCS-01 has the potential to become the first topical preservative-free eye drop for the treatment of DME, the leading cause of vision loss and legal blindness in patients with diabetes.

Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms

Retrieved on: 
Saturday, March 18, 2023
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Maintenance, Psoriasis Area and Severity Index, EASI, Week, Dermatology, American Academy, Atopic dermatitis, IGA, 2008 Giro d'Italia, Stage 1 to Stage 11, Patient, Itch, AD, Skin, Inflammation, Vaccine

Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, announced that data from Stage 1 of the ongoing pivotal CBP-201 China trial in moderate-to-severe atopic dermatitis (AD) showed rapid relief from symptoms, as early as week one in some cases, and no efficacy plateau at Week 16.

Key Points: 
  • Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, announced that data from Stage 1 of the ongoing pivotal CBP-201 China trial in moderate-to-severe atopic dermatitis (AD) showed rapid relief from symptoms, as early as week one in some cases, and no efficacy plateau at Week 16.
  • In the study “CBP-201, a next-generation IL-4Rα antibody, achieved all primary and secondary efficacy endpoints in the treatment of adults with moderate-to-severe atopic dermatitis (AD): A randomized, double-blind, pivotal trial in China (CBP-201-CN002),” researchers reported on results from Stage 1 of the pivotal China trial of CBP-201 in moderate-to-severe AD.
  • Patients on active therapy experienced rapid relief of symptoms, with a reduction in itch at Week 1 and significant improvement in all study endpoints by Week 4, which was sustained to Week 16.
  • “We are honored to have data from our two CBP-201 atopic dermatitis studies at the prestigious American Academy of Dermatology Annual Meeting, showing rapid and sustained relief,” said Zheng Wei, Ph.D., Co-founder and CEO of Connect Biopharma.

Dakar Victory for TOYOTA GAZOO Racing as Al-attiyah/Baumel Take the Win

Retrieved on: 
Monday, January 17, 2022
City, 2012 Giro d'Italia, Stage 12 to Stage 21, Toyota Hilux, Toyota, Hope, Memory, Toyota Gazoo Racing, Qatar, DOC, Arab world, The Great Gazoo, Dakar Rally, 2008 Giro d'Italia, Stage 1 to Stage 11, Technical director, Shameer Mon, Villiers, Engineering, Nightclub, Entertainment

This victory is significant for Nasser, as he has expressed the hope to win in the Arab world since the Dakar first moved to Saudi Arabia in 2020.

Key Points: 
  • This victory is significant for Nasser, as he has expressed the hope to win in the Arab world since the Dakar first moved to Saudi Arabia in 2020.
  • He came agonisingly close in both 2020 and 2021, before securing his first win in Saudi Arabia in 2022.
  • I'd like to dedicate this win to the memory of Dr. Johan van Zyl, who was a visionary leader and consistent supporter of the TOYOTA GAZOO Racing Dakar project over many years.
  • I'd like to thank TOYOTA GAZOO Racing and all our sponsors for the support.